Protocol for the P3BEP Trial (ANZUP 1302): An International Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Adult and Paediatric Male and Female Patients With Intermediate and Poor-Risk Metastatic Germ Cell Tumours

BMC Cancer - United Kingdom
doi 10.1186/s12885-018-4745-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Accelerated BEP: A Phase I Trial of Dose-Dense BEP for Intermediate and Poor Prognosis Metastatic Germ Cell Tumour

British Journal of Cancer
Cancer ResearchOncology
2011English

Is CBOP/BEP an Alternative to BEP for Patients With Poor Prognosis Metastatic Germ Cell Tumours?

ESMO Open
Cancer ResearchOncology
2016English

Familial Predisposition to Both Male and Female Germ Cell Tumours?

Journal of Medical Genetics
Genetics
1996English

The CLOSED Trial; CLOnidine Compared With Midazolam for SEDation of Paediatric Patients in the Intensive Care Unit: Study Protocol for a Multicentre Randomised Controlled Trial

BMJ Open
Medicine
2017English

Does Intensive Management Improve Remission Rates in Patients With Intermediate Rheumatoid Arthritis? (The TITRATE Trial): Study Protocol for a Randomised Controlled Trial

Trials
MedicinePharmacology
2017English

Multidisciplinary and Multifaceted Outpatient Management of Patients With Osteoarthritis: Protocol for a Randomised, Controlled Trial

BMC Musculoskeletal Disorders
RheumatologyOrthopedicsSports Medicine
2010English

Randomized Trial of Legflow® Paclitaxel Eluting Balloon and Stenting Versus Standard Percutaneous Transluminal Angioplasty and Stenting for the Treatment of Intermediate and Long Lesions of the Superficial Femoral Artery (RAPID Trial): Study Protocol for a Randomized Controlled Trial

Trials
MedicinePharmacology
2013English

Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial

The Lancet
Medicine
2012English

Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial

The Lancet
Medicine
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy